ClearPoint Neuro (NASDAQ:CLPT) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of ClearPoint Neuro (NASDAQ:CLPT - Free Report) from a sell rating to a hold rating in a report released on Saturday.

Separately, Stifel Nicolaus upped their price objective on shares of ClearPoint Neuro from $19.00 to $25.00 and gave the company a "buy" rating in a report on Tuesday, April 1st.

ClearPoint Neuro Stock Performance

Shares of NASDAQ:CLPT traded down $0.43 during midday trading on Friday, reaching $11.17. The company's stock had a trading volume of 310,176 shares, compared to its average volume of 245,061. The firm has a market capitalization of $312.65 million, a price-to-earnings ratio of -14.70 and a beta of 0.93. The firm has a 50 day moving average price of $12.82 and a two-hundred day moving average price of $14.31. ClearPoint Neuro has a fifty-two week low of $5.11 and a fifty-two week high of $19.22.

ClearPoint Neuro (NASDAQ:CLPT - Get Free Report) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.07). ClearPoint Neuro had a negative net margin of 64.51% and a negative return on equity of 78.09%. The business had revenue of $8.49 million during the quarter, compared to analyst estimates of $8.21 million. As a group, research analysts anticipate that ClearPoint Neuro will post -0.66 earnings per share for the current year.

Insider Transactions at ClearPoint Neuro

In related news, Director Timothy T. Richards sold 10,000 shares of the company's stock in a transaction dated Tuesday, June 10th. The shares were sold at an average price of $13.28, for a total value of $132,800.00. Following the sale, the director now owns 77,381 shares in the company, valued at $1,027,619.68. This represents a 11.44% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Joseph Burnett sold 21,247 shares of the stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $13.29, for a total value of $282,372.63. Following the completion of the sale, the chief executive officer now directly owns 243,522 shares of the company's stock, valued at approximately $3,236,407.38. This trade represents a 8.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. 6.11% of the stock is owned by insiders.

Institutional Investors Weigh In On ClearPoint Neuro

A number of institutional investors and hedge funds have recently bought and sold shares of CLPT. AlphaQuest LLC purchased a new stake in shares of ClearPoint Neuro in the fourth quarter valued at about $80,000. Deutsche Bank AG purchased a new stake in ClearPoint Neuro in the 1st quarter valued at about $63,000. Tower Research Capital LLC TRC purchased a new stake in ClearPoint Neuro in the 4th quarter valued at about $93,000. State of Wyoming purchased a new stake in shares of ClearPoint Neuro during the fourth quarter valued at approximately $145,000. Finally, Occudo Quantitative Strategies LP purchased a new stake in shares of ClearPoint Neuro during the fourth quarter valued at approximately $155,000. 30.08% of the stock is owned by hedge funds and other institutional investors.

ClearPoint Neuro Company Profile

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.